KIT and neoplasm: As imatinib, a tyrosine kinase inhibitor, exerts anti‐tumour effects on feline MCTs harbouring KIT exon 8 or 9 ITD via the inhibition of phosphorylation (Isotani et al., 2010), the treatment response to toceranib in this case was assessed using a similar mechanism.